LY2562175
| CAS No. | 1103500-20-4 | Cat. No. | BCP33226 |
| Name | LY2562175 | ||
| Synonyms | LY 2562175; LY-2562175; | ||
| Formula | C28H27Cl2N3O4 | M. Wt | 540.44 |
| Description | LY2562175 is a potent and selective FXR agonist in vitro and has robust lipid modulating properties, lowering LDL and triglycerides while raising HDL in preclinical species. The preclinical ADME properties of LY2562175 were consistent with enabling once daily dosing in humans, and it was ultimately advanced to the clinic for evaluation in humans. LY2562175 promotes transcriptional activation of human FXR in a cell-based cotransfection assay with an EC50 of 193 nM (geometric mean). | ||
| Pathways | Protease/Metabolic Enzyme | ||
| Targets | FXR | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.